Trial Profile
Chiba Refractory Schizophrenia Treatment-LAI study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 May 2016
Price :
$35
*
At a glance
- Drugs Risperidone (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- Acronyms CREST
- 03 May 2016 Status changed from active, no longer recruiting to completed.
- 25 Jul 2012 New trial record